Author:
Engelhardt Monika,Wäsch Ralph,Reinhardt Heike,Kleber Martina
Publisher
Springer Berlin Heidelberg
Reference33 articles.
1. Baz R, Shain KH, Alsina M, Nardelli LA, Nishihori T, Ochoa L, Martin T, Jagannath S, Dalton W, Sullivan DM (2012) Oral weekly cyclophosphamide in combination with pomalidomide and dexamethasone for relapsed and refractory myeloma: report of the dose escalation cohort. Blood 120:4062
2. Begna KH, Mesa RA, Pardanani A, Hogan WJ, Litzow MR, McClure RF, Tefferi A (2011) A phase-2 trial of low-dose pomalidomide in myelofibrosis. Leukemia 25:301–304
3. Berenson JR, Hilger JD, Klein LM, Eshaghian S, Nassir Y, Swift RA, Vescio R (2012) A phase 1/2 study of pomalidomide, dexamethasone and pegylated liposomal doxorubicin for patients with relapsed/refractory multiple myeloma. Blood 120:2979
4. Corral LG, Haslett PA, Muller GW, Chen R, Wong LM, Ocampo CJ, Patterson RT, Stirling DI, Kaplan G (1999) Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-alpha. J Immunol 163:380–386
5. D’Amato R, Lentzsch S, Anderson KC, Rogers MS (2001) Mechanism of action of thalidomide and 3-aminothalidomide in multiple myeloma. Semin Oncol 28:597–601
Cited by
13 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献